Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy
Beáta Biri-Kovács1, Zoltán Bánóczi1,2, Anitha Tummalapally1
1ELKH-ELTE Research Group of Peptide Chemistry, 1117 Budapest, Hungary.
Abstract:
Cancer of the skin is by far the most common of all cancers. Although the incidence of melanoma is relatively low among skin cancers, it can account for a high number of skin cancer deaths. Since the start of deeper insight into the mechanisms of melanoma tumorigenesis and their strong interaction with the immune system, the development of new therapeutical strategies has been continuously rising. The high number of melanoma cell mutations provides a diverse set of antigens that the immune system can recognize and use to distinguish tumor cells from normal cells. Peptide-based synthetic anti-tumor vaccines are based on tumor antigens that elicit an immune response due to antigen-presenting cells (APCs). Although targeting APCs with peptide antigens is the most important assumption for vaccine development, peptide antigens alone are poorly immunogenic. The immunogenicity of peptide antigens can be improved not only by synthetic modifications but also by the assistance of adjuvants and/or delivery systems. The current review summarizes the different chemical approaches for the development of effective peptide-based vaccines for the immunotherapeutic treatment of advanced melanoma.
Insights
This review explores chemical strategies to enhance peptide-based vaccines for advanced melanoma immunotherapy. Improving the immunogenicity of these vaccines is key to effectively targeting melanoma tumors.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Melanoma is a common cancer with a high mortality rate.
- Melanoma's interaction with the immune system offers therapeutic targets.
- Tumor antigens from melanoma mutations can be recognized by the immune system.
Purpose of the Study:
- To review chemical approaches for developing effective peptide-based vaccines for advanced melanoma.
- To summarize methods for improving the immunogenicity of peptide antigens.
- To discuss the role of antigen-presenting cells (APCs) in melanoma immunotherapy.
Main Methods:
- Review of chemical modifications and synthetic approaches for peptide antigens.
- Analysis of adjuvants and delivery systems to enhance vaccine efficacy.
- Summary of current research on peptide-based melanoma vaccines.
Main Results:
- Peptide antigens alone have limited immunogenicity.
- Synthetic modifications, adjuvants, and delivery systems can improve peptide vaccine effectiveness.
- Targeting APCs is crucial for eliciting an immune response against melanoma.
Conclusions:
- Chemical strategies are vital for creating effective peptide-based melanoma vaccines.
- Enhancing immunogenicity is essential for successful immunotherapy of advanced melanoma.
- Further research into synthetic modifications and delivery systems holds promise for melanoma treatment.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...